Mazindol for Cocaine Abuse - 2

This study has been completed.
Sponsor:
Collaborators:
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00000277
First received: September 20, 1999
Last updated: July 24, 2013
Last verified: December 2002
  Purpose

The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Mazindol
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Mazindol for Cocaine Abuse

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Side effects
  • Drug use
  • Retention

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000277

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

No publications provided

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000277     History of Changes
Other Study ID Numbers: NIDA-09250-2, P50DA009250, P50-09250-2
Study First Received: September 20, 1999
Last Updated: July 24, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Mazindol
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Dopamine Agents

ClinicalTrials.gov processed this record on August 28, 2014